Galectin Therapeutics stock holds a $399.36 million valuation

Galectin Therapeutics Inc. (US3631621074) had a market capitalization of USD 399.36 million as of September 22, 2026, giving GALT stock a clearly defined biotechnology valuation anchor. The figure comes alongside a reported public float of 47.32 million shares.

Valuation sets the current anchor

The USD 399.36 million market capitalization and 47.32 million-share float were listed for Galectin Therapeutics in an 8-K filing overview dated September 22, 2026, by Stock Titan. The comparison between the total valuation and the float matters because it frames the stock as a small-cap biotechnology security rather than a diversified pharmaceutical company.

The same September 22, 2026 filing page classifies Galectin Therapeutics in the biotechnology industry and reports the 47.32 million-share float against the USD 399.36 million market value. That produces a market-cap-to-float figure of about USD 8.44 per floating share, although it is not a trading price and should not be treated as one.

Biotechnology classification matters

GALT remains tied to the biotechnology sector, where valuation is commonly driven by clinical development, regulatory milestones and financing capacity rather than established product revenue alone. The September 22, 2026 classification therefore gives the stock a sector context, while the USD 399.36 million valuation provides the dated market figure.

For investors assessing Galectin Therapeutics, the numerical contrast is the key point: 47.32 million shares were identified as the float against a total market capitalization of USD 399.36 million. That relationship makes changes in trial expectations or capital requirements potentially material to the valuation framework, but the available dated filing overview does not establish a new clinical result, revenue figure or earnings comparison.

Stock value stays the reference point

GALT stock is best described through the confirmed market data available for September 22, 2026: USD 399.36 million in market capitalization, 47.32 million shares in the public float and a biotechnology industry classification. The figures provide a concrete baseline for later price, clinical and financing updates.

Galectin Therapeutics stock therefore enters September 23, 2026 with a documented USD 399.36 million market value as of September 22, 2026. The biotechnology label and 47.32 million-share float remain the central dated reference points.

More news and analyses on Galectin Therapeutics stock